Vinita Kailasanath

2 months ago | medcitynews.com | Vinita Kailasanath |Shannon O’Hara

Vinita Kailasanath, a partner in the Silicon Valley office of Freshfields, has extensive experience in strategic intellectual property and data-driven transactions in life sciences and technology, and particularly at their intersection.

Nov 15, 2024 | healthcarebusinesstoday.com | Brock Dahl |Vinita Kailasanath

The healthcare industry is no stranger to cybersecurity risk concerns. In the last few years, the world has witnessed several instances of cybersecurity threats and interferences, from cyberattacks on customer accounts containing prescription information, to ransomware attacks on patient records systems and health payment processing companies, and exploitation of vulnerabilities in DNA sequencing instruments.

May 9, 2024 | lexology.com | Andrew Dockham |Beth George |Adam Golden |Vinita Kailasanath |Kristen Riemenschneider |Madeline Cimino | +1 more

Following legislation forcing ByteDance’s divestment in TikTok, anti-China sentiment on Capitol Hill has refocused on restricting the federal government from contracting companies that contract with biotech firms linked to foreign adversaries. Legislation being considered on both sides of Capitol Hill takes an aggressive stance.

May 9, 2024 | blog.freshfields.us | Andrew Dockham |Beth George |Adam Golden |Vinita Kailasanath

Following legislation forcing ByteDance’s divestment in TikTok, anti-China sentiment on Capitol Hill has refocused on restricting the federal government from contracting companies that contract with biotech firms linked to foreign adversaries. Legislation being considered on both sides of Capitol Hill takes an aggressive stance.

Jan 22, 2024 | lexology.com | Adam Golden |Vinita Kailasanath |Kristen Riemenschneider |Dylan O'Connor |Shannon O'Hara

The 42nd Annual J.P. Morgan Healthcare Conference brought together thousands of professionals in the biopharma, biotech and MedTech spaces to discuss the latest industry developments and forge new partnerships. Coming off an extremely active Q4 2023, the excitement over what may be in store in 2024 was palpable. However, lingering doubt continued to hover over the minds of many, with concerns about the financing environment, drug pricing reform, and looming gaps in product pipelines.